Simon B Ascher1,2, Rebecca Scherzer1, Michelle M Estrella1, William R Zhang1, Anthony N Muiru1, Vasantha Jotwani1, Carl Grunfeld1,3, Chirag R Parikh4, Deborah Gustafson5, Mary Young6, Anjali Sharma7, Mardge H Cohen8, Derek K Ng9, Frank J Palella10, Mallory D Witt11, Ken Ho12, Michael G Shlipak13,3. 1. Department of Medicine, Kidney Health Research Collaborative, San Francisco Veterans Affairs Medical Center, San Francisco, California. 2. Department of Medicine, University of California, Los Angeles, Los Angeles, California. 3. Department Epidemiology, and Biostatistics, University of California, San Francisco, San Francisco, California. 4. Section of Nephrology, Department of Medicine, Yale University, New Haven, Connecticut. 5. Department of Neurology, The State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York. 6. Division of Infectious Diseases, Department of Medicine, Georgetown University Medical Center, Washington, DC. 7. Department of Medicine, Albert Einstein College of Medicine, Bronx, New York. 8. Department of Medicine, Stroger Hospital and Rush University, Chicago, Illinois. 9. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 10. Division of Infectious Diseases, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 11. Department of Medicine, Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles Medical Center, Torrance, California; and. 12. Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. 13. Department of Medicine, Kidney Health Research Collaborative, San Francisco Veterans Affairs Medical Center, San Francisco, California; michael.shlipak@ucsf.edu.
Abstract
BACKGROUND AND OBJECTIVES: Tenofovir disoproxil fumarate (tenofovir) is associated with elevated concentrations of biomarkers of kidney damage and dysfunction in individuals with HIV. The relationship of these kidney biomarkers with longitudinal kidney function decline is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We evaluated associations of 14 urinary biomarkers of kidney injury with changes in eGFR among 198 men and women with HIV who initiated tenofovir between 2009 and 2015 in the Multicenter AIDS Cohort Study and Women's Interagency HIV Study. Urinary biomarkers included albumin-to-creatinine ratio, α-1-microglobulin, β-2-microglobulin, cystatin C, kidney injury molecule-1 (KIM-1), IL-18, neutrophil gelatinase-associated lipocalin (NGAL), clusterin, osteopontin, uromodulin, monocyte chemoattractant protein-1, EGF, trefoil factor 3, and chitinase 3-like protein 1. We used multivariable linear mixed-effect models controlling for demographics, traditional kidney disease risk factors, and HIV-related risk factors to evaluate associations of baseline biomarkers with first-year changes in eGFR, and associations of year 1 and first-year change in biomarkers with changes in eGFR from year 1 to year 3. We used the least absolute shrinkage and selection operator method to identify a parsimonious set of biomarkers jointly associated with changes in eGFR. RESULTS: Median eGFR before tenofovir initiation was 103 (interquartile range, 88-116) ml/min per 1.73 m2. During the first year of tenofovir use, eGFR decreased on average by 9.2 (95% confidence interval, 6.5 to 11.9) ml/min per 1.73 m2 and was stable afterward (decrease of 0.62; 95% confidence interval, -0.85 to 2.1 ml/min per 1.73 m2 per year). After multivariable adjustment, higher baseline β-2-microglobulin, KIM-1, and clusterin were associated with larger first-year eGFR declines, whereas higher baseline uromodulin was associated with a smaller eGFR decline. First-year increase in urinary cystatin C and higher year 1 IL-18 were associated with larger annual eGFR declines from year 1 to year 3. The parsimonious models identified higher pre-tenofovir clusterin and KIM-1, lower pre-tenofovir uromodulin, and higher year 1 IL-18 as jointly associated with larger eGFR declines. CONCLUSIONS: Urinary biomarkers of kidney injury measured before and after tenofovir initiation are associated with subsequent changes in eGFR in individuals with HIV. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_08_28_CJASNPodcast_18_9_S.mp3.
BACKGROUND AND OBJECTIVES:Tenofovir disoproxil fumarate (tenofovir) is associated with elevated concentrations of biomarkers of kidney damage and dysfunction in individuals with HIV. The relationship of these kidney biomarkers with longitudinal kidney function decline is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We evaluated associations of 14 urinary biomarkers of kidney injury with changes in eGFR among 198 men and women with HIV who initiated tenofovir between 2009 and 2015 in the Multicenter AIDS Cohort Study and Women's Interagency HIV Study. Urinary biomarkers included albumin-to-creatinine ratio, α-1-microglobulin, β-2-microglobulin, cystatin C, kidney injury molecule-1 (KIM-1), IL-18, neutrophil gelatinase-associated lipocalin (NGAL), clusterin, osteopontin, uromodulin, monocyte chemoattractant protein-1, EGF, trefoil factor 3, and chitinase 3-like protein 1. We used multivariable linear mixed-effect models controlling for demographics, traditional kidney disease risk factors, and HIV-related risk factors to evaluate associations of baseline biomarkers with first-year changes in eGFR, and associations of year 1 and first-year change in biomarkers with changes in eGFR from year 1 to year 3. We used the least absolute shrinkage and selection operator method to identify a parsimonious set of biomarkers jointly associated with changes in eGFR. RESULTS: Median eGFR before tenofovir initiation was 103 (interquartile range, 88-116) ml/min per 1.73 m2. During the first year of tenofovir use, eGFR decreased on average by 9.2 (95% confidence interval, 6.5 to 11.9) ml/min per 1.73 m2 and was stable afterward (decrease of 0.62; 95% confidence interval, -0.85 to 2.1 ml/min per 1.73 m2 per year). After multivariable adjustment, higher baseline β-2-microglobulin, KIM-1, and clusterin were associated with larger first-year eGFR declines, whereas higher baseline uromodulin was associated with a smaller eGFR decline. First-year increase in urinary cystatin C and higher year 1 IL-18 were associated with larger annual eGFR declines from year 1 to year 3. The parsimonious models identified higher pre-tenofovirclusterin and KIM-1, lower pre-tenofoviruromodulin, and higher year 1 IL-18 as jointly associated with larger eGFR declines. CONCLUSIONS: Urinary biomarkers of kidney injury measured before and after tenofovir initiation are associated with subsequent changes in eGFR in individuals with HIV. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_08_28_CJASNPodcast_18_9_S.mp3.
Authors: Frank Dieterle; Elias Perentes; André Cordier; Daniel R Roth; Pablo Verdes; Olivier Grenet; Serafino Pantano; Pierre Moulin; Daniel Wahl; Andreas Mahl; Peter End; Frank Staedtler; François Legay; Kevin Carl; David Laurie; Salah-Dine Chibout; Jacky Vonderscher; Gérard Maurer Journal: Nat Biotechnol Date: 2010-05 Impact factor: 54.908
Authors: A G Norden; M Lapsley; P J Lee; C D Pusey; S J Scheinman; F W Tam; R V Thakker; R J Unwin; O Wrong Journal: Kidney Int Date: 2001-11 Impact factor: 10.612
Authors: Hassane Izzedine; Jean Sebastien Hulot; Daniel Vittecoq; Joel E Gallant; Schlomo Staszewski; Vincent Launay-Vacher; Andrew Cheng; Gilbert Deray Journal: Nephrol Dial Transplant Date: 2005-03-01 Impact factor: 5.992
Authors: James J Kohler; Seyed H Hosseini; Amy Hoying-Brandt; Elgin Green; David M Johnson; Rodney Russ; Dung Tran; C Michael Raper; Robert Santoianni; William Lewis Journal: Lab Invest Date: 2009-03-09 Impact factor: 5.662
Authors: Chirag R Parikh; Alkesh Jani; Vyacheslav Y Melnikov; Sarah Faubel; Charles L Edelstein Journal: Am J Kidney Dis Date: 2004-03 Impact factor: 8.860
Authors: Ivica Grgic; Gabriela Campanholle; Vanesa Bijol; Chang Wang; Venkata S Sabbisetti; Takaharu Ichimura; Benjamin D Humphreys; Joseph V Bonventre Journal: Kidney Int Date: 2012-03-21 Impact factor: 10.612
Authors: Jonathan G Amatruda; Ronit Katz; Carmen A Peralta; Michelle M Estrella; Harini Sarathy; Linda F Fried; Anne B Newman; Chirag R Parikh; Joachim H Ix; Mark J Sarnak; Michael G Shlipak Journal: J Am Geriatr Soc Date: 2020-12-10 Impact factor: 5.562
Authors: Anthony N Muiru; Rebecca Scherzer; Simon B Ascher; Vasantha Jotwani; Carl Grunfeld; Judy Shigenaga; Kimberly A Spaulding; Derek K Ng; Deborah Gustafson; Amanda B Spence; Anjali Sharma; Mardge H Cohen; Chirag R Parikh; Joachim H Ix; Michelle M Estrella; Michael G Shlipak Journal: BMC Nephrol Date: 2021-08-30 Impact factor: 2.585
Authors: William R Zhang; Rebecca Scherzer; Michelle M Estrella; Simon B Ascher; Anthony Muiru; Vasantha Jotwani; Carl Grunfeld; Chirag R Parikh; Deborah Gustafson; Seble Kassaye; Anjali Sharma; Mardge Cohen; Phyllis C Tien; Derek K Ng; Frank J Palella; Mallory D Witt; Ken Ho; Michael G Shlipak Journal: AIDS Date: 2019-03-15 Impact factor: 4.177
Authors: S B Ascher; R Scherzer; M M Estrella; A N Muiru; V K Jotwani; C Grunfeld; J Shigenaga; K A Spaulding; D K Ng; D Gustafson; A B Spence; A Sharma; M H Cohen; C R Parikh; J H Ix; M G Shlipak Journal: HIV Med Date: 2021-03-09 Impact factor: 3.094
Authors: Simon B Ascher; Rebecca Scherzer; Michelle M Estrella; Judy Shigenaga; Kimberly A Spaulding; David V Glidden; Megha L Mehrotra; Patricia Defechereux; Monica Gandhi; Robert M Grant; Michael G Shlipak; Vasantha Jotwani Journal: AIDS Date: 2020-04-01 Impact factor: 4.632